Literature DB >> 1267820

Tumour inhibitory triazenes: structural requirements for an active metabolite.

T A Connors, P M Goddard, K Merai, W C Ross, D E Wilman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1267820     DOI： 10.1016/0006-2952(76)90207-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  15 in total

1.  Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization.

Authors:  Di Bei; Tao Zhang; James B Murowchick; Bi-Botti C Youan
Journal:  AAPS PharmSciTech       Date:  2010-08-06       Impact factor: 3.246

2.  Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes.

Authors:  G Sava; S Zorzet; L Perissin; T Giraldi; L Lassiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK.

Authors:  G Sava; S Zorzet; L Perissin; S Pacor; L Lassiani; C Nisi; A Varnavas
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity.

Authors:  T Colombo; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 5.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 6.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  In vitro biotransformation of carbinolamine metabolites of cytotoxic dimethyltriazenes [proceedings].

Authors:  A Gescher; J A Hickman; M F Stevens
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

8.  Triazene drug metabolites: part 15. Synthesis and plasma hydrolysis of anticancer triazenes containing amino acid carriers.

Authors:  E Carvalho; J Iley; M J Perry; E Rosa
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

9.  Microsomal mediated metabolism of dialkylaryltriazenes. II. Isolation and identification of metabolites of 3,3-dimethyl-1-phenyltriazene.

Authors:  B L Pool
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

10.  Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.

Authors:  L L Tsang; C P Quarterman; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.